Abstract:Objective: To evaluate if induction chemotherapy, with or without irradiation, represents an additional risk factor for early and late morbidity and perioperative mortality in bronchoplastic procedures for lung cancers. Methods: From January 1998 to January 2001, 27 patients underwent a bronchial sleeve resection after induction treatment at the European Institute of Oncology in Milan. They represent 7% of lung cancer resections (387) and 27% of those performed after neoadjuvant treatment (100 cases). Histology was: 17 epidermoid carcinoma, 8 adenocarcinoma and 2 SCLC. Twenty-four patients (89%) received a preoperative cisplatin based polichemotherapy, and three cases (11%) a chemo-radiation therapy. A right sleeve lobectomy or bilobectomy was undertaken in 21 patients (78%) and a left lobectomy in 6 (22%). A resection of tracheal carina was associated in three cases and a vascular resection in 10 (five vena cava and five pulmonary artery). Twelve patients (44%) received adjuvant mediastinal irradiation. Perioperative morbidity of the study group (group 1) was compared with that of patients submitted to sleeve resection without neoadjuvant treatment (group 2), or standard pneumonectomy after induction treatment (group 3). Results: There were no postoperative deaths. A major perioperative complication occurred in two patients (7%) of group 1, one patient of group 2 (3.5%), and four in group 3 (17%). Among patients of the study group, no anastomotic dehiscence or pleural empyema were observed. Only one late anastomotic stricture occurred after postoperative radiation treatment. No significant difference in early and late complication rate was found between the three groups of patients. High rate of complete resection was achieved (93%) in patients of the study group and extent of nodal dissection was similar between sleeve resections and pneumonectomy patients. Conclusions: Preoperative chemotherapy or combination of chemo-radio therapy is not associated with an additional risk of anastomotic complications in bronco and angioplastic procedures. Parenchyma sparing resection is a valid option for selected patients with locally advanced lung cancer after induction treatment. A longer follow up is necessary to evaluate efficacy of the procedure in term of survival and local control.

Optimal timing of surgery for bronchial sleeve resection after neoadjuvant chemoradiotherapy

Bronchus Anastomosis Healing Depending on Type of Neoadjuvant Therapy

Sleeve resections with unprotected bronchial anastomoses are safe even after neoadjuvant therapy

The incidence of perioperative anastomotic complications after sleeve lobectomy is not increased after neoadjuvant chemoradiotherapy

Impact of induction therapy on airway complications after sleeve lobectomy for lung cancer

Low morbidity of bronchoplastic procedures after chemotherapy for lung cancer

Sleeve lobectomy after induction chemoradiotherapy

Extended sleeve lobectomy after induction chemoradiotherapy for non-small cell lung cancer

Techniques and Outcomes of Bronchoplastic and Sleeve Resection: an 8-Year Single-Center Experience.

Safety and Efficacy of Neoadjuvant Chemoimmunotherapy versus Chemotherapy for Non-Small Cell Lung Cancer Undergoing Sleeve Resection

Feasibility of sleeve lobectomy after neo-adjuvant chemo-immunotherapy in non-small cell lung cancer

Sleeve lobectomy versus lobectomy for primary treatment of non-small-cell lung cancer: A single-center retrospective analysis

Video-assisted Thoracoscopic Surgery Sleeve Lobectomy with Bronchoplasty

Sleeve lobectomy versus pneumonectomy following neoadjuvant therapy in patients with non-small cell lung cancer

Comparison of video-assisted thoracoscopic surgery with thoracotomy in bronchial sleeve lobectomy for centrally located non-small cell lung cancer

Evaluation of Risk Factors for Early Insufficiency after Bronchial Sleeve Resections

Bronchial and arterial sleeve resection after induction therapy for lung cancer

Survival Outcomes of Neoadjuvant Therapy Followed by Sleeve Lobectomy in Non-Small Cell Lung Cancer

Effect of Interval Between Neoadjuvant Chemoradiotherapy and Surgery on Oncological Outcomes in Poor Responders with Locally Advanced Rectal Cancer: a Retrospective Cohort Study.

Three years follow-up of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer

Neoadjuvant therapy does not increase postoperative morbidity of sleeve lobectomy in locally advanced non-small cell lung cancer